IP Library Granted Patent US 7,972,803
Granted Patent B2
US 7,972,803 · App. 11/985,545 · Granted Jul 5, 2011

Centrosomal proteins and secretion

Assignee: University of Massachusetts
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,972,803
App. No.
11/985,545
Granted
Jul 5, 2011
Kind
B2
Abstract

Described are methods for modulating cellular secretion, and methods for identifying novel modulators of cellular secretion, that target centrosomal proteins.

Claims (36)

1. An in vitro method of identifying a candidate modulator of insulin secretion, the method comprising:

providing a cell that expresses pericentrin;

contacting the cell with a test compound;

detecting an effect of the test compound on levels of expression of pericentrin; and

identifying the test compound as a candidate modulator of insulin secretion if the test compound increases or decreases expression of pericentrin.

2. The method of claim 1 , wherein the cell is an insulin-secreting cell.

3. The method of claim 2 , wherein the insulin-secreting cell is a pancreatic beta cell.

4. The method of claim 2 , wherein the insulin-secreting cell is a MIN6 cell.

5. The method of claim 1 , wherein the test compound is a small molecule.

6. The method of claim 1 , wherein the test compound is an inhibitory nucleic acid.

7. The method of claim 1 , further comprising evaluating an effect of the test compound on insulin secretion in an insulin-secreting cell, wherein a test compound that has an effect on insulin secretion in the insulin-secreting cell is identified as a modulator of insulin secretion.

8. The method of claim 7 , wherein the insulin-secreting cell is a pancreatic beta cell.

9. The method of claim 7 , wherein the insulin-secreting cell is a MIN6 cell.

10. An in vitro method of identifying a candidate modulator of insulin secretion, the method comprising:

providing a cell expressing a reporter construct comprising a pericentrin promoter linked to a reporter gene, such that expression of the reporter gene is indicative of expression driven by the pericentrin promoter;

contacting the cell with a test compound;

detecting an effect of the test compound on levels of expression of the reporter gene; and

identifying the test compound as a candidate modulator of insulin secretion if the test compound increases or decreases expression of the reporter gene.

11. The method of claim 10 , wherein the cell is an insulin-secreting cell.

12. The method of claim 11 , wherein the insulin-secreting cell is a pancreatic beta cell.

13. The method of claim 11 , wherein the insulin-secreting cell is a MIN6 cell.

14. The method of claim 10 , wherein the test compound is a small molecule.

15. The method of claim 10 , wherein the test compound is an inhibitory nucleic acid.

16. The method of claim 10 , further comprising evaluating an effect of the test compound on insulin secretion in an insulin-secreting cell, wherein a test compound that has an effect on insulin secretion in the insulin-secreting cell is identified as a modulator of insulin secretion.

17. The method of claim 16 , wherein the insulin-secreting cell is a pancreatic beta cell.

18. The method of claim 16 , wherein the insulin-secreting cell is a MIN6 cell.

19. An in vitro method of identifying an agent that modulates insulin secretion in a cell, the method comprising:

selecting a test compound on the basis that it increases or decreases expression levels of a pericentrin;

providing an insulin-secreting cell that expresses pericentrin;

contacting the cell with the test compound;

evaluating an effect of the test compound on insulin secretion in the cell; and

identifying the test compound as an agent that modulates insulin secretion if the test compound has an effect on insulin secretion in the cell.

20. The method of claim 19 , wherein the insulin-secreting cell is a pancreatic beta cell.

21. The method of claim 19 , wherein the insulin-secreting cell is a MIN6 cell.

22. The method of claim 19 , wherein the test compound is an inhibitory nucleic acid.

23. The method of claim 19 , wherein the test compound is an inhibitory nucleic acid.

Assignments (3)
CONFIRMATORY LICENSE Recorded Aug 3, 2011
From: UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026691/0600 →
CONFIRMATORY LICENSE Recorded Sep 18, 2008
From: UNIVERSITY OF MASSACHUSETTS MEDICAL SC
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021549/0995 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2008
From: JURCZYK, AGATA; BORTELL, RITA BELLIS; ROSSINI, ALDO A.; DOXSEY, STEPHEN J.
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 021513/0883 →
Continuity (2)
Provisional Application 60859383 · Nov 15, 2006
Related Publication 20090029935A1 · Jan 29, 2009